Dyax Corp. (DYAX, Financial) filed Quarterly Report for the period ended 2012-06-30.
Dyax Corp. has a market cap of $269.7 million; its shares were traded at around $2.45 with and P/S ratio of 5.5.
Selling, General and Administrative. Our selling, general and administrative expenses consist primarily of the sales and marketing costs of commercializing KALBITOR, costs of our management and administrative staff, as well as expenses related to business development, protecting our intellectual property, administrative occupancy, professional fees and the reporting requirements of a public company. Selling, general and administrative expenses for the 2012 and 2011 Quarters were $10.4 million and $9.1 million, respectively. Costs increased during the 2012 Quarter primarily due to continued expansion of infrastructure and initiatives to support further commercialization of the KALBITOR product.
Revenues. Total revenues for the six months ended June 30, 2012 (the 2012 Period) were $25.5 million, compared with $30.1 million for the six months ended June 30, 2011 (the 2011 Period).
Costs associated with obtaining regulatory approval for the treatment of HAE in territories outside the United States were $56,000 and $1.4 million during 2012 and 2011, respectively. These amounts were reimbursed by Sigma Tau and such payments are recorded as development and license fee revenue in our results of operations.
Selling, General and Administrative. Our selling, general and administrative expenses consist primarily of the sales and marketing costs of commercializing KALBITOR, costs of our management and administrative staff, as well as expenses related to business development, protecting our intellectual property, administrative occupancy, professional fees and the reporting requirements of a public company. Selling, general and administrative expenses for the 2012 and 2011 Periods were $20.8 million and $18.3 million, respectively. Costs increased during the 2012 Period primarily due to continued expansion of infrastructure and initiatives to support further commercialization of the KALBITOR product.
Read the The complete Report
Dyax Corp. has a market cap of $269.7 million; its shares were traded at around $2.45 with and P/S ratio of 5.5.
Highlight of Business Operations:
Revenues. Total revenues for the three months ended June 30, 2012 (the 2012 Quarter) were $14.0 million, compared with $21.9 million for the three months ended June 30, 2011 (the 2011 Quarter).Selling, General and Administrative. Our selling, general and administrative expenses consist primarily of the sales and marketing costs of commercializing KALBITOR, costs of our management and administrative staff, as well as expenses related to business development, protecting our intellectual property, administrative occupancy, professional fees and the reporting requirements of a public company. Selling, general and administrative expenses for the 2012 and 2011 Quarters were $10.4 million and $9.1 million, respectively. Costs increased during the 2012 Quarter primarily due to continued expansion of infrastructure and initiatives to support further commercialization of the KALBITOR product.
Revenues. Total revenues for the six months ended June 30, 2012 (the 2012 Period) were $25.5 million, compared with $30.1 million for the six months ended June 30, 2011 (the 2011 Period).
Costs associated with obtaining regulatory approval for the treatment of HAE in territories outside the United States were $56,000 and $1.4 million during 2012 and 2011, respectively. These amounts were reimbursed by Sigma Tau and such payments are recorded as development and license fee revenue in our results of operations.
Selling, General and Administrative. Our selling, general and administrative expenses consist primarily of the sales and marketing costs of commercializing KALBITOR, costs of our management and administrative staff, as well as expenses related to business development, protecting our intellectual property, administrative occupancy, professional fees and the reporting requirements of a public company. Selling, general and administrative expenses for the 2012 and 2011 Periods were $20.8 million and $18.3 million, respectively. Costs increased during the 2012 Period primarily due to continued expansion of infrastructure and initiatives to support further commercialization of the KALBITOR product.
Read the The complete Report
